Key result
In patients with active cancer and venous thromboembolism, rivaroxaban treatment resulted in a 6-month cumulative incidence of recurrent VTE of 4.4% and major bleeding of 2.2%.
Why the study?
Does rivaroxaban prevent recurrent VTE without excessive bleeding in patients with cancer-associated thrombosis?
Cohort (n=200)
No
Does rivaroxaban prevent recurrent VTE without excessive bleeding in patients with cancer-associated thrombosis?
Rivaroxaban appears safe and effective for the treatment of cancer-associated thrombosis, with rates of recurrent VTE and major bleeding comparable to historical data for low-molecular-weight heparin.
Answers are grounded in this paper and cite their sources.
May support rivaroxaban evaluation in CAT; leaves open randomized confirmation versus LMWH.
Low-molecular weight heparin (LMWH) has been the standard of care for treatment of venous thromboembolism (VTE) in patients with cancer. Rivaroxaban was approved in 2012 for the treatment of pulmonary embolism (PE) and deep vein thrombosis (DVT), but no prior studies have been reported specifically evaluating the efficacy and safety of rivaroxaban for cancer-associated thrombosis (CAT). Under a Quality Assessment Initiative (QAI), we established a Clinical Pathway to guide rivaroxaban use for CAT and now report a validation analysis of our first 200 patients. A 200 patient cohort with CAT (PE or symptomatic, proximal DVT), whose full course of anticoagulation was with rivaroxaban, were accrued. In competing risk analysis, primary endpoints at 6 months included new or recurrent PE or symptomatic proximal lower extremity DVT, major bleeding, clinically-relevant non-major bleeding leading to discontinuation of rivaroxaban, or death. In competing risk analysis, the 6 months cumulative incidence of new or recurrent VTE was 4.4 % (95 % CI = 1.4-7.4 %), major bleeding was 2.2 % (95 % CI = 0-4.2 %) and all-cause mortality 17.6 % (95 % CI = 11.7-23.0 %). In this cohort of 200 patients with active cancer and CAT the rates of new or recurrent VTE and major bleeding were comparable to the cancer subgroup analysis from the EINSTEIN studies. The results of our Clinical Pathway provide guidance on Rivaroxaban use for treatment of CAT, and suggest that safety and efficacy is preserved, compared with past-published experience with LMWH.
No takes yet. Share an insight, caveat, or question.
Mantha et al. (2016) conducted a cohort in Cancer-associated venous thromboembolic disease (n=200). Rivaroxaban was evaluated on New or recurrent VTE at 6 months (95% CI 1.4-7.4). In patients with active cancer and venous thromboembolism, rivaroxaban treatment resulted in a 6-month cumulative incidence of recurrent VTE of 4.4% and major bleeding of 2.2%.
Synapse has enriched 10 related papers. Consider them for comparative context: